IVAC: Intravenous Acetaminophen for Craniotomy Patients

Sponsor
Swedish Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT01474304
Collaborator
Mallinckrodt (Industry)
80
1
2

Study Details

Study Description

Brief Summary

Adding intraoperative IV acetaminophen, in addition to standard analgesics, will decrease opioid requirements over the first 12 hours of postoperative recovery following craniotomy. Opioids exacerbate symptoms of nausea and vomiting. Reducing postoperative opioid use hopefully will reduce incidence of nausea and vomiting in patients after craniotomy.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Intravenous Acetaminophen for Craniotomy Patients: A Single-blinded, Randomized Controlled Trial to Evaluate the Effect of Intravenous Acetaminophen Administered at Induction and Emergence From Craniotomy
Study Start Date :
Nov 1, 2011
Anticipated Primary Completion Date :
Jun 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Acetaminophen

Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.

Drug: Acetaminophen
1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery

No Intervention: No acetaminophen

Patients will receive standard of care with no intraoperative doses of acetaminophen.

Outcome Measures

Primary Outcome Measures

  1. Total narcotic dose administered over the first 12 hours of postoperative recovery. [12 hours]

    Intensive care nurses will ask subject about pain and nausea every 15 minutes for the first two hours immediately after surgery and then every hour afterward for up to 12 hours. Nurses will record subject response and opioid doses given.

Secondary Outcome Measures

  1. Incidence of nausea during postoperative recovery [12 hours]

  2. Incidence of vomiting during postoperative recovery [12 hours]

  3. Severity of nausea during postoperative recovery [12 hours]

  4. Severity of vomiting during postoperative recovery [12 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • At least 18 years of age

  • Weigh at least 50 kg (110.23 lbs)

  • Undergoing open, elective intracranial procedure for

  • tumor resection

  • aneurysm clipping

  • revascularization

  • Have an ASA (American Society of Anesthesiologists) physical status of 1, 2, 3, or 4

  • Able to provide written informed consent

Exclusion Criteria:
  • Significant medical disease, laboratory abnormality, or condition that, in the opinion of the investigator, would compromise patient welfare or would otherwise contraindicate study participation

  • Unable to communicate symptoms

  • Current daily opioid use (>40 mg morphine equivalent)

  • Tramadol use

  • Treated with MAO (monoamine oxidase inhibitors) inhibitors within 10 days of surgery

  • Treated with any amount of acetaminophen within 8 hours of anesthesia for surgery

  • Allergic or hypersensitive to acetaminophen or any contraindications per manufacturer's guidelines

  • Pregnancy

  • Impaired liver function

  • Participation in interventional clinical study within the last 30 days

  • Known or suspected history of alcohol or drug abuse

  • Surgery for resection of acoustic neuroma

  • Transphenoidal tumor resection

Contacts and Locations

Locations

Site City State Country Postal Code
1 Swedish Medical Center Cherry Hill Campus Seattle Washington United States 98122

Sponsors and Collaborators

  • Swedish Medical Center
  • Mallinckrodt

Investigators

  • Principal Investigator: Arthur Lam, MD, FRCPC, Swedish Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Swedish Medical Center
ClinicalTrials.gov Identifier:
NCT01474304
Other Study ID Numbers:
  • IVAC
  • 20111619
First Posted:
Nov 18, 2011
Last Update Posted:
Sep 29, 2016
Last Verified:
Sep 1, 2016
Keywords provided by Swedish Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 29, 2016